Search / Trial NCT06223555

Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose

Launched by NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES (NIDDK) · Jan 24, 2024

Trial Information

Current as of December 21, 2024

Recruiting

Keywords

Healthy Volunteer Obesity Body Composition Diet Mixed Meal Test Glucose

ClinConnect Summary

This clinical trial is studying how different meal sizes affect blood sugar levels in healthy adults. Researchers want to find out whether using a fixed meal size, which is the same for everyone, or an adjusted meal size, based on a person's body size, is better for understanding how our bodies respond to food. This information will help improve future research on how we process meals.

To participate in this study, you must be a healthy adult aged 18 or older. You'll need to visit the clinic 3 or 4 times over 8 weeks, where you'll undergo some tests, including measuring your height and weight, and taking a sugary drink to see how your body handles glucose. You'll also have two visits where you'll eat a liquid meal, one with a fixed size and one adjusted to your needs, while your blood is tested over a few hours. It's important to note that you won't be eligible if you have certain health conditions, are pregnant, or are taking specific medications.

Gender

ALL

Eligibility criteria

  • * INCLUSION CRITERIA:
  • In order to be eligible to participate in this study, an individual must meet all of the following criteria:
  • Provision of signed and dated informed consent form.
  • Agreement to adhere to Lifestyle Considerations throughout study duration.
  • Males and females; Age \>= 18years
  • Healthy, as determined by medical history, physical examination, and laboratory tests.
  • EXCLUSION CRITERIA:
  • An individual who meets any of the following criteria will be excluded from participation in this
  • study:
  • Current use of medications, dietary supplements, or alternative therapies known to alter energy metabolism.
  • Fasting plasma glucose \>= 126 mg/dL
  • Type I or Type II Diabetes Mellitus by self-report.
  • Hematologic disorders including significant anemia (male hemoglobin \< 13.0 g/dL or female hemoglobin \< 11.0 g/dL)
  • Current pregnancy, pregnancy within the past 6 months or currently lactating
  • History or self-report of gastrointestinal disease, including inflammatory bowel diseases (e.g. Chron s disease and ulcerative colitis), malabsorption syndromes (e.g. celiac disease), gastric ulcer (active) which may alter metabolism or absorption of study food by self-report
  • Evidence of alcohol abuse as defined by an 8-point score on the Alcohol consumption screening AUDIT questionnaire in adults.
  • Participants who report taking large doses of acetaminophen (\> 3 grams daily) who cannot stop acetaminophen 24 hours prior to and following the meal tests will be excluded from the study.
  • Inability to consume provided food based on a food allergy or intolerance.
  • Conditions not specifically mentioned above may serve as criteria for exclusion at the discretion of the investigators.
  • Any disorder, unwillingness, or inability not covered by any other exclusion criteria which, in the investigator s and/or team s opinion, jeopardizes the safety of the participant or others or would interfere with adherence to the protocol (such as claustrophobia).
  • Conditions not specifically mentioned above may serve as criteria for exclusion at the discretion of the investigators.

Trial Officials

Susi M Votruba, Ph.D.

Principal Investigator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

About National Institute Of Diabetes And Digestive And Kidney Diseases (Niddk)

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is a prominent research institution within the National Institutes of Health (NIH) dedicated to advancing scientific knowledge and promoting health in the areas of diabetes, endocrine and metabolic disorders, obesity, digestive diseases, and kidney diseases. Through rigorous clinical trials and innovative research initiatives, NIDDK aims to improve prevention, diagnosis, and treatment strategies, ultimately enhancing patient outcomes and quality of life. The institute fosters collaboration among researchers, healthcare professionals, and community stakeholders to drive impactful discoveries and translate findings into effective healthcare solutions.

Locations

Phoenix, Arizona, United States

Phoenix, Arizona, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0